|
|
Geron Corporation
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Big Plus- FDA approves trial changesFrom Geron press release- The company has
received clearance from the FDA to expand eligibility criteria from
injuries between spinal segments T3 and T10 to include patients with
injuries at T11. In addition, the FDA has approved that the current 30
day period between subjects in the trial may be reduced to 10 days. |
|
|
return to message board, top of board |
